17 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 23 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Completed 17, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow Vulvar Neoplasms: new trials by email Literature Review of Vulvar Neoplasms trials Research Report on Vulvar Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Randomised Clinical Trial of Ultrasound Groin Monitoring Versus Groin Lymph Node Dissection to De-Escalate the Extent of Surgery in Vulvar Cancer High-resolution bilateral groin ultrasound monitoring - Vulvar Cancer Stage I, Vulvar Cancer Stage II | Phase 3 | Not yet recruiting | Queensland Centre for Gynaecological Cancer | 640 | 2026-06-01 | 2026-03-24 |
| A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9 - Human Papillomavirus Infection | Phase 3 | Active not recruiting | Beijing Health Guard Biotechnology, Inc | 2750 | 2022-03-23 | 2022-12-27 |
| Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years 9-valent HPV vaccine - HPV Infections, Cervical Cancer | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2021-05-28 | 2024-04-17 |
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9 - HPV Infections, Cervical Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2020-09-19 | 2023-11-24 |
| Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Completed | Shanghai Bovax Biotechnology Co., Ltd. | 1680 | 2020-05-28 | 2022-02-25 |
| Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 8000 | 2020-04-28 | 2024-06-07 |
| Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) 9vHPV vaccine - Papillomavirus Infections, Uterine Cervical Neoplasms | Phase 3 | Completed | Merck Sharp & Dohme LLC | 201 | 2018-06-29 | 2020-02-25 |
| Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Indocyanine green, Technetium99, Optonuclear probe - Breast Carcinoma, Head and Neck Cancer | Phase 3 | Completed | Institut de Cancérologie de Lorraine | 744 | 2017-11-29 | 2026-09-01 |
| Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) V503 - Cervical Cancer, Vulvar Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1212 | 2017-09-20 | 2019-11-21 |
| Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms prasterone, placebo - Breast Cancer, Gynecologic Cancer | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 464 | 2011-07-01 | 2019-02-07 |
| GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™), Placebo - Papillomavirus Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 250 | 2011-03-21 | 2018-11-14 |
| A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) V503, Placebo to V503 - Cervical Cancers, Vulvar Cancers | Phase 3 | Completed | Merck Sharp & Dohme LLC | 924 | 2010-02-24 | 2018-11-27 |
| A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) V503 - Cervical Cancers, Vulvar Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 3074 | 2009-08-27 | 2022-10-03 |
| Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence Tension free vaginal tape, Bulking agent injection - Urinary Incontinence, Stress | Phase 3 | Completed | University Magna Graecia | 40 | 2009-05-01 | 2013-04-08 |
| Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Management of Therapy Complications, Quality-of-Life Assessment - Lymphedema, Stage 0 Cervical Cancer | Phase 3 | Terminated | Gynecologic Oncology Group | 2 | 2007-12-01 | 2021-06-23 |
| Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Fentanyl sublingual spray, Placebo - Cancer | Phase 3 | Completed | INSYS Therapeutics Inc | 130 | 2007-10-01 | 2014-03-05 |
| Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Comparator: GARDASIL, Experimental: V503 - Cervical Cancer, Vulvar Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 14840 | 2007-09-24 | 2018-11-27 |
| Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage ultracision, classical lymphadenectomy - Vulvar Neoplasms, Skin Neoplasms | Phase 3 | Completed | Institut Claudius Regaud | 73 | 2005-11-01 | 2014-09-12 |
| Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva fibrin sealant, surgical wound closure - Lymphedema, Perioperative/Postoperative Complications | Phase 3 | Completed | Gynecologic Oncology Group | 2003-01-01 | 2013-07-09 | |
| Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis octreotide acetate, placebo, radiation - Cervical Cancer, Colorectal Cancer | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 130 | 2002-04-01 | 2016-07-13 |
Showing 20 of 23. Sign in to see all of them.
Uterine Cervical Neoplasms (16) · Vaginal Neoplasms (14) · Condylomata Acuminata (10) · Papillomavirus Infections (8) · Endometrial Neoplasms (4) · Anus Neoplasms (3) · Breast Neoplasms (3) · Fallopian Tube Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Lymphedema (2) · Melanoma (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2)
Female Urogenital Diseases (23) · Female Urogenital Diseases and Pregnancy Complications (23) · Genital Diseases (23) · Genital Diseases, Female (23) · Genital Neoplasms, Female (23) · Neoplasms by Site (23) · Urogenital Diseases (23) · Urogenital Neoplasms (23) · Vulvar Diseases (23) · Neoplasms (21) · Pathological Conditions, Signs and Symptoms (16) · Uterine Cervical Diseases (16) · Uterine Diseases (16) · Uterine Neoplasms (16) · Pathologic Processes (14)
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (3) · Radiotherapy (2) · Vaccines, Synthetic (2) · Cisplatin (1) · Dehydroepiandrosterone (1) · Fentanyl (1) · Fibrin Tissue Adhesive (1) · Indocyanine Green (1) · Infracyanine green (1) · Octreotide (1) · Papillomavirus Vaccines (1) · Radiation (1) · Suburethral Slings (1) · Technetium-99 (1) · Vaccines (1)
Merck Sharp & Dohme LLC (6) · Gynecologic Oncology Group (5) · Shanghai Bovax Biotechnology Co., Ltd. (4) · Alliance for Clinical Trials in Oncology (2) · Beijing Health Guard Biotechnology, Inc (1) · INSYS Therapeutics Inc (1) · Institut Claudius Regaud (1) · Institut de Cancérologie de Lorraine (1) · Queensland Centre for Gynaecological Cancer (1) · University Magna Graecia (1)
United States (6) · China (5) · France (2) · Italy (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Finland (1) · Germany (1) · Spain (1) · Vietnam (1)
Andreas Obermair, MD (1) · Charles Levenback, MD (1) · Debra Barton, RN, PhD, AOCN, FAAN (1) · Denis Querleu, Pr (1) · George C. Lewis, MD (1) · Gillian M. Thomas, BSc, MD, FRCPC, FRCR (Hon) (1) · James A. Martenson, MD (1) · Jay W. Carlson, DO (1) · Larry Dillaha, MD (1) · Levi Downs (1) · Yongjiang Liu, Bachelor (1)
PMID 27422279, PMID 29211620, PMID 29269325, PMID 29767739, PMID 18482765, PMID 18768432, PMID 19701032, PMID 22480131, PMID 22753905, PMID 25278227, PMID 25693011, PMID 25749310, PMID 25912208, PMID 25912475, PMID 26086587, PMID 26101366, PMID 26366475, PMID 26411885, PMID 27020837, PMID 28789851, PMID 28886907, PMID 30982556, PMID 32659510, PMID 33326342, PMID 33676783, PMID 33844623, PMID 37667847, PMID 3785783, PMID 41166720
2009 (1), 2017 (1), U10CA101165 (1)